Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is an open randomised phase II study evaluating the anti-tumour activity, safety and
pharmacology of two dose regimens of IPH2101, a human monoclonal anti-KIR antibody, in
patients with multiple myeloma in stable partial response after a first line therapy.